Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2016 50 998 M
EBIT 2016 18 253 M
Net income 2016 11 541 M
Debt 2016 10 591 M
Yield 2016 3,38%
Sales 2017 53 660 M
EBIT 2017 19 700 M
Net income 2017 12 685 M
Debt 2017 4 976 M
Yield 2017 3,60%
P/E ratio 2016 18,37
P/E ratio 2017 16,70
EV / Sales 2016 4,48x
EV / Sales 2017 4,16x
Capitalization 218 128 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the diagnostics and pharmaceuticals segments.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The diagnostic segment... 
Sector
Pharmaceuticals
Calendar
06/03 | 10:00pmPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
05/26 REMINDER : Invitation to Roche Analyst Event at ASCO 2016
05/24 CHUGAI PHARMACEUTICAL : Anti-Cancer Agent 'Avastin,' Obtained Approval for Addit..
05/24 ROCHE : Lariam only to be considered as a last resort, says Defence Committee
05/24 ROCHE : Lariam should be 'drug of last resort' for troops
05/24 ROCHE : MPs say malaria drug Lariam should only be used by UK troops as 'last re..
05/24 ROCHE : MPs sound alarm over British troops' use of malaria drug Lariam
05/23 ROCHE : GSK Price to Drop 67% in China
05/23 ROCHE : Charles Aznavour is 92
More news
Sector news : Pharmaceuticals - NEC
02:04a PFIZER : Shortage of penicillin threatens treatment for those with syphilis
12:51a TARO PHARMACEUTICAL : posts 4Q profit
12:34a TARO PHARMACEUTICAL : Provides Results for Year Ended March 31, 2016
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions